Lower systolic blood pressure reduces risk of stroke – Older people with systolic blood pressure lower than 140 millimeters of mercury (mm Hg) have a lower risk of stroke, revealed in a study study presented at the American Stroke Association’s International Stroke Conference 2015.
FDA approves pediatric use of Dexcom’s G4 Platinum continuous glucose monitoring system – The U.S. Food and Drug Administration today approved the expanded use of the Dexcom G4 Platinum Continuous Monitoring System for patients with diabetes ages 2 to 17 years. The G4 Platinum System, which monitors blood glucose levels in people with diabetes, had been approved for patients ages 18 and older.
Duration of diabetes and advancing age independently predict diabetes complications, risk of death – The duration of diabetes and advancing age independently predict diabetes severity and risk of death in older adults with type 2 diabetes. In a new study led by Kaiser Permanente and the University of Chicago, researchers investigated contemporary rates of diabetes complications and risk of death then contrasted them across categories of age and duration of diabetes.
Pazopanib shows better quality-of-life in advanced kidney cancer – Two oral targeted drugs — Pazopanib (Votrient) and sunitinib (Sutent) — approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, the safety profile and many measures of quality of life favored pazopanib.
Use of ADT For Treatment of Prostate Cancer Linked With Increased Risk of Kidney Injury – Androgen deprivation therapy (ADT) for nonmetastatic prostate cancer was associated with a significantly increased risk of acute kidney injury, according to a study that included more than 10,000 men published in JAMA.
Urine test can diagnose, predict kidney transplant rejection — NIH-funded study describes noninvasive alternative to kidney biopsy – Analysis of three biomarkers in the urine of kidney transplant recipients can diagnose — and even predict — transplant rejection, according to results from a clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.